Arcus Biosciences (NYSE: RCUS) reported Q2 EPS of ($0.72), $0.18 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $41 million versus the consensus estimate of $22.22 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.